Skip to main content

Table 3 Level of IgG antibodies in patients to different malaria antigens in relation to treatment outcome.

From: Potential impact of host immunity on malaria treatment outcome in Tanzanian children infected with Plasmodium falciparum

 

Median level (25th and 75th percentiles)*

 

Antigen

TF, n = 53

ACPR, n = 47

P-value

GLURP-R0

0.0 (0.0–1.3)

8.4 (0.0–47.7)

< 0.001

GLURP-R2

0.0 (0.0–5.0)

7.7 (0.0–49.8)

< 0.001

AMA-1

24.3 (0.0–51.1)

24.5 (0.0–87.3)

0.25

CSP

5.8 (0.0–17.1)

10.2 (0.0–24.4)

0.42

CIDR1α

15.4 (3.3–61.7)

9.1 (0.0–30.2)

0.24

DBL2β

22.5 (6.9–45.6)

16.9 (3.4–58.3)

0.92

DBL4γ-DBL5δ

10.4 (1.6–38.6)

12.4 (3.0–44.0)

0.74

MSP-1

80.0 (6.7–144.4)

122.7 (29.3–162.0)

0.11

MSP-3

5.3 (1.1–12.6)

8.0 (2.5–18.9)

0.30

VSA1

15.5 (5.2–33.0)

19.8 (6.1–41.0)

0.58

VSA2

16.3 (4.1–30.9)

21.1 (7.6–38.7)

0.21

EBA-175

4.3 (0.0–14.1)

5.9 (0.0–21.0)

0.54

SCHIZONT

30.0 (12.9–51.0)

35.2 (11.1–80.2)

0.17

  1. TF: Parasitological or clinical treatment failure, ACPR: Adequate clinical and parasitological response. Patients receiving sulphadoxine-pyrimethamine (SP) or amodiaquine (AQ) are grouped together. *Median values of IgG level day 0 in arbitrary units (25th and 75th percentiles). P-values determined by Mann-Whitney rank-sum test. Similar tendencies were observed when restricting the analysis to those with a measurable antibody level only, and when analysing each drug arm separately. For definitions of antigens, see Figure 1 and in the method section.